Merck And Cardiome Obtain EU Approval For Vernakalant In Atrial Fibrillation
This article was originally published in The Pink Sheet Daily
Executive Summary
First of several anticipated approvals for the AF drug nets Cardiome a $30 million milestone payment from Merck.
You may also be interested in...
Merck Drops Development Of Cardiome’s Oral Vernakalant
Higher regulatory hurdles for anti-arrhythmic drugs have pushed Merck to discontinue the development of Cardiome’s oral vernakalant.
Xention Siphons Off OAB Therapy Into New Spin Out, Provesica
Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica
Xention Siphons Off OAB Therapy Into New Spin Out, Provesica
Atrial fibrillation will be Xention's focus following the spin-out of its overactive bladder assets into a new company, Provesica